ReviewThe Journal of physiology2016
Sympathetic-mediated activation versus suppression of the immune system: consequences for hypertension.
Review in The Journal of physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Ablation of cancer cell secreted neuropeptide PTHLH/PTHrP provokes anti-tumor immunity in murine tongue squamous cell carcinoma.Scientific reports · 2026Article
- Bioinformatics Screening of Tumor-Derived Neuropeptides Mediating Neuroimmune Axis of Head and Neck Cancer.Cancers · 2025Article
- Exploring the complex interplay: gut microbiome, stress, and leptospirosis.Frontiers in microbiology · 2024Review
- Incidence and risk factors for norovirus-related diarrhea in Japanese geriatric intermediate care facilities: A prospective cohort study.Geriatrics & gerontology international · 2023Article
- The role of the immune system in posttraumatic stress disorder.Translational psychiatry · 2022Review
- The carotid body: A novel key player in neuroimmune interactions.Frontiers in immunology · 2022Review
- High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients.Frontiers in immunology · 2022Article
- Hypertension and its management in COVID-19 patients: The assorted view.International journal of cardiology. Cardiovascular risk and prevention · 2021Review
- Natural killer cells, gamma delta T cells and classical monocytes are associated with systolic blood pressure in the multi-ethnic study of atherosclerosis (MESA).BMC cardiovascular disorders · 2021Observational
- Prevalence, Clinical Manifestations, and Biochemical Data of Hypertensive versus Normotensive Symptomatic Patients with COVID-19: A Comparative Study.Acta bio-medica : Atenei Parmensis · 2020Article
- Cardiometabolic risk factors are associated with immune cell mitochondrial respiration in humans.American journal of physiology. Heart and circulatory physiology · 2020Article
- Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?Current hypertension reports · 2020Review
- From early adversities to immune activation in psychiatric disorders: the role of the sympathetic nervous system.Clinical and experimental immunology · 2019Review
- Immune mechanisms of hypertension.Nature reviews. Immunology · 2019Review
- Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.Pharmacological research · 2019Review
- Treatment Trends, Complications, and Effects of Comorbidities on Distal Radius Fractures.Hand (New York, N.Y.) · 2019Article
- The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.British journal of pharmacology · 2019Review
- Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.American journal of physiology. Heart and circulatory physiology · 2019Article
- Loneliness, Social Isolation, and Cardiovascular Health.Antioxidants & redox signaling · 2018Review
- Targeting neural reflex circuits in immunity to treat kidney disease.Nature reviews. Nephrology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It is generally well-accepted that the immune system is a significant contributor in the pathogenesis of hypertension. Specifically, activated and pro-inflammatory T-lymphocytes located primarily in the vasculature and kidneys appear to have a causal role in exacerbating elevated blood pressure. It has been proposed that increased sympathetic nerve activity and noradrenaline outflow associated with hypertension may be primary contributors to the initial activation of the immune system early in the disease progression. However, it has been repeatedly demonstrated in many different human and experimental diseases that sympathoexcitation is immunosuppressive in nature. Moreover, human hypertensive patients have demonstrated increased susceptibility to secondary immune insults like infections. Thus, it is plausible, and perhaps even likely, that in diseases like hypertension, specific immune cells are activated by increased noradrenaline, while others are in fact suppressed. We propose a model in which this differential regulation is based upon activation status of the immune cell as well as the resident organ. With this, the concept of global immunosuppression is obfuscated as a viable target for hypertension treatment, and we put forth the concept of focused organ-specific immunotherapy as an alternative option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.